From the below no mention of cutting anti viral orders only vaccine orders. So no news is good news IMO.
"Fears of a swine flu pandemic triggered soaring demand for GlaxoSmithKline's antiviral vaccines from governments around the world.
Europe's biggest drugs maker reported sales of flu vaccine Relenza rocketed to 256 million in the last three months of 2009, up from 13 million in the same period the year before.
Total sales from H1N1 flu pandemic vaccines for the year reached 883 million, helping Glaxo to report a rise in underlying pre-tax profits to 8.7 billion for 2009, up from 7.8 billion in 2008.
Chief executive Andrew Witty said he expected similar shipments in H1N1 vaccines in 2010 as in 2009.
But the windfall won't last, and some countries are cutting vaccine orders as the pandemic proves to be less serious than originally feared."
